4,483 reports of this reaction
2.0% of all TACROLIMUS reports
#10 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #10 most commonly reported adverse reaction for TACROLIMUS, manufactured by Astellas Pharma US, Inc.. There are 4,483 FDA adverse event reports linking TACROLIMUS to CYTOMEGALOVIRUS INFECTION. This represents approximately 2.0% of all 222,557 adverse event reports for this drug.
TACROLIMUS has an overall safety score of 90 out of 100. Patients taking TACROLIMUS who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is a less commonly reported adverse event for TACROLIMUS, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for TACROLIMUS:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 4,483 FDA reports for TACROLIMUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 2.0% of all adverse event reports for TACROLIMUS, making it a notable side effect.
If you experience cytomegalovirus infection while taking TACROLIMUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.